ENTERA BIO LTD (ENTX) Fundamental Analysis & Valuation

NASDAQ:ENTX • IL0011429839

Current stock price

1.12 USD
-0.05 (-4.27%)
Last:

This ENTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ENTX Profitability Analysis

1.1 Basic Checks

  • In the past year ENTX has reported negative net income.
  • ENTX had a negative operating cash flow in the past year.
  • In the past 5 years ENTX always reported negative net income.
  • ENTX had a negative operating cash flow in each of the past 5 years.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • ENTX's Return On Assets of -71.53% is on the low side compared to the rest of the industry. ENTX is outperformed by 65.70% of its industry peers.
  • Looking at the Return On Equity, with a value of -87.31%, ENTX is in line with its industry, outperforming 46.51% of the companies in the same industry.
Industry RankSector Rank
ROA -71.53%
ROE -87.31%
ROIC N/A
ROA(3y)-82.9%
ROA(5y)-79.03%
ROE(3y)-96.99%
ROE(5y)-91.25%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ENTX Health Analysis

2.1 Basic Checks

  • ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ENTX has been increased compared to 1 year ago.
  • ENTX has more shares outstanding than it did 5 years ago.
  • ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of 0.28, we must say that ENTX is in the distress zone and has some risk of bankruptcy.
  • ENTX has a Altman-Z score (0.28) which is in line with its industry peers.
  • ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.28
ROIC/WACCN/A
WACC8.53%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • ENTX has a Current Ratio of 6.94. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ENTX (6.94) is better than 66.47% of its industry peers.
  • ENTX has a Quick Ratio of 6.94. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.94, ENTX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.94
Quick Ratio 6.94
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ENTX Growth Analysis

3.1 Past

  • The earnings per share for ENTX have decreased by -4.00% in the last year.
  • Looking at the last year, ENTX shows a very negative growth in Revenue. The Revenue has decreased by -76.80% in the last year.
  • Measured over the past years, ENTX shows a very negative growth in Revenue. The Revenue has been decreasing by -35.28% on average per year.
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-76.8%
Revenue growth 3Y-31.38%
Revenue growth 5Y-35.28%
Sales Q2Q%-100%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-166.77%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENTX Dividend Analysis

5.1 Amount

  • ENTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENTX Fundamentals: All Metrics, Ratios and Statistics

ENTERA BIO LTD

NASDAQ:ENTX (4/24/2026, 8:00:02 PM)

1.12

-0.05 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-08
Inst Owners20.01%
Inst Owner Change0%
Ins Owners2.88%
Ins Owner Change3.29%
Market Cap60.98M
Revenue(TTM)42.00K
Net Income(TTM)-11.44M
Analysts82.86
Price Target10.2 (810.71%)
Short Float %0.5%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.75%
Min EPS beat(2)23.75%
Max EPS beat(2)23.75%
EPS beat(4)4
Avg EPS beat(4)27.5%
Min EPS beat(4)15.97%
Max EPS beat(4)46.52%
EPS beat(8)7
Avg EPS beat(8)12.48%
EPS beat(12)10
Avg EPS beat(12)12.46%
EPS beat(16)14
Avg EPS beat(16)15.3%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1452
P/FCF N/A
P/OCF N/A
P/B 4.65
P/tB 4.65
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -71.53%
ROE -87.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.9%
ROA(5y)-79.03%
ROE(3y)-96.99%
ROE(5y)-91.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 356.67%
Cap/Sales 254.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.94
Quick Ratio 6.94
Altman-Z 0.28
F-Score3
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)131.18%
Cap/Depr(5y)103.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-166.77%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.8%
Revenue growth 3Y-31.38%
Revenue growth 5Y-35.28%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.1%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERA BIO LTD / ENTX Fundamental Analysis FAQ

What is the fundamental rating for ENTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENTX.


Can you provide the valuation status for ENTERA BIO LTD?

ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.


Can you provide the profitability details for ENTERA BIO LTD?

ENTERA BIO LTD (ENTX) has a profitability rating of 0 / 10.


What is the financial health of ENTERA BIO LTD (ENTX) stock?

The financial health rating of ENTERA BIO LTD (ENTX) is 8 / 10.